Survey Assessing Prospective Patient's Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Cosentyx (Secukinumab) in Routine Clinical Practice in Saudi Arabia: ILLUMINATE-SA
Latest Information Update: 05 Jan 2026
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms ILLUMINATE-SA
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 30 Dec 2025 Planned End Date changed from 30 Jan 2026 to 30 Sep 2026.
- 30 Dec 2025 Planned primary completion date changed from 30 Jan 2026 to 30 Sep 2026.
- 30 Dec 2025 Status changed from not yet recruiting to recruiting.